U.S. Media Stock News

The Whitehawk Therapeutics, Inc. ( NASDAQ:WHWK ) share price has done very well over the last month, posting an...

Loop Industries, Inc. ( NASDAQ:LOOP ) shareholders are no doubt pleased to see that the share price has bounced 28% in...

Atlassian Corporation ( NASDAQ:TEAM ) shareholders that were waiting for something to happen have been dealt a blow...

Despite an already strong run, Drilling Tools International Corporation ( NASDAQ:DTI ) shares have been powering on...

Anyone interested in Ares Commercial Real Estate Corporation ( NYSE:ACRE ) should probably be aware that the CEO...

Personalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 28% after a shaky period...

Stem, Inc. ( NYSE:STEM ) shareholders are no doubt pleased to see that the share price has bounced 29% in the last...

Some StepStone Group Inc. ( NASDAQ:STEP ) shareholders may be a little concerned to see that insider James Lim recently...

In recent days, Illumina announced the launch of its Billion Cell Atlas, a large-scale CRISPR-based single-cell dataset built with founding participants including Merck, AstraZeneca and Eli Lilly, while reports also surfaced that Merck is in early-stage talks to acquire cancer drug developer Revolution Medicines in a potential US$28.00 billion to US$32.00 billion transaction. Merck also began a Phase 3 trial of its KRAS G12C inhibitor calderasib combined with subcutaneous KEYTRUDA QLEX in...

Celsius Holdings, Inc. ( NASDAQ:CELH ) shareholders are no doubt pleased to see that the share price has bounced 33% in...

If you are wondering whether Coherent's stock still offers value after a strong run, you are not alone. This article will walk through what the current price could mean for long term investors. Coherent closed at US$191.04, with returns of 7.3% over the last 7 days, 12.1% over the last 30 days, a 1.7% decline year to date, and 94.4% over the last year. The 3 year return is very large at 346.6% and the 5 year return sits at 103.5%. Recent headlines around Coherent have focused on its position...

Vertex Pharmaceuticals recently reported strong 2025 third-quarter results and outlined its 2026 pipeline and business plans, highlighting continued growth in its cystic fibrosis franchise alongside expanding contributions from CASGEVY for blood disorders and JOURNAVX for acute pain. Investors and fund managers are increasingly focused on how Vertex’s diversified pipeline and new launches might offset rising costs and margin pressure amid intensifying competition. We’ll now examine how...

If you have been wondering whether Flowserve's recent share price puts it on the expensive or attractive side of fair value, this breakdown is designed to give you a clear, grounded view of what you are really paying for. Flowserve shares last closed at US$77.17, with returns of 5.0% over 7 days, 11.5% over 30 days, 9.1% year to date, 23.4% over 1 year, 144.6% over 3 years and 122.0% over 5 years. This naturally raises questions about how much future upside or risk is currently reflected in...

If you are wondering whether Norfolk Southern's current share price reflects its true worth, you are not alone. This article is designed to help you size up what you are really paying for. The stock last closed at US$290.63, with returns of 1.2% over the past week, a 1.3% decline over the past month, and 21.0% over the past year, which has many investors reassessing both upside potential and risk. Recent attention around Norfolk Southern has focused on its operations, capital plans, and...

Murphy Oil (MUR) is back in focus after reporting a significant oil discovery at its Hai Su Vang-2X appraisal well offshore Vietnam, which has prompted higher recoverable resource estimates and plans for additional appraisal work. See our latest analysis for Murphy Oil. The discovery comes after a strong 90 day share price return of 21.71% and a 1 year total shareholder return of 10.72%. However, the 3 year total shareholder return of a 10.04% decline contrasts with a very large 5 year total...

Wondering whether IPG Photonics stock still offers value after a rough few years and a recent rebound, or if the price already reflects what you are paying for? This article walks through the key clues in the current valuation. The share price recently closed at US$81.75, with returns of 7.4% over 7 days, 9.3% over 30 days, 9.2% year to date, but a 24.0% decline over 3 years and a 67.4% decline over 5 years. These mixed returns sit alongside ongoing discussion around IPG Photonics' position...

Investors may be wondering if Baker Hughes at around US$51.75 is offering fair value today, or if the price is getting ahead of itself. The stock has recent returns of 3.6% over 7 days, 16.4% over 30 days, 9.8% year to date, 13.6% over 1 year, 78.8% over 3 years and 165.2% over 5 years, which has many investors reassessing both its potential and the risks they are willing to take. Recent coverage on Baker Hughes has focused on its position as a major energy services provider and how changing...

If you are wondering whether Western Digital's current share price still offers value after a strong run, you are not alone. That question is exactly what this article will unpack. The stock last closed at US$221.51, with returns of 10.5% over 7 days, 33.2% over 30 days, 18.0% year to date, 352.4% over 1 year, and a very large gain over 3 and 5 years that is more than 7x. Recent headlines around Western Digital have focused on its position in data storage and memory solutions and how...

If you are wondering whether Estée Lauder Companies is attractively priced or if the recent buzz has already been factored in, this article walks you through what the current share price might be implying. The stock last closed at US$115.05, with returns of 1.2% over 7 days, 9.3% over 30 days, 7.8% year to date and 50.4% over 1 year, set against longer term returns of a 54.6% decline over 3 years and a 50.5% decline over 5 years. Recent coverage around Estée Lauder has focused on how...

Recent performance snapshot Sempra (SRE) has drawn fresh attention after recent price moves, with the stock closing at $92.55 and posting gains over the past week, month, past 3 months, and year. For context, the company reports annual revenue of about US$13.7b and net income of roughly US$2.1b, with both revenue and earnings showing positive annual growth based on the latest figures provided. See our latest analysis for Sempra. The recent 1 month share price return of 6.65% and 1 year total...

Leadership transition at AIG and why it matters for shareholders American International Group (AIG) is entering a planned leadership transition, as Chairman and CEO Peter Zaffino prepares to move to Executive Chair while Eric Andersen steps in as CEO-elect from February 2026. The handover comes after a multi year succession process, during which AIG’s board searched for a leader to continue focusing on performance over the long term. For shareholders, the move puts the spotlight on how the...

Why Ameren (AEE) is on investors’ radar today Ameren (AEE) has drawn attention after recent share price moves, with the stock last closing at $104. For investors, the key question is how this regulated utility’s fundamentals line up with that price. See our latest analysis for Ameren. Recent trading has been relatively firm, with a 7 day share price return of 4.1% and a 30 day share price return of 5.6%, while the 1 year total shareholder return sits at 13.7%. This suggests momentum has...

ProPetro Holding Corp. has scheduled the release of its fourth-quarter and full-year 2025 results for February 18, 2026, accompanied by a conference call and webcast to review the performance. This upcoming earnings update gives investors a fresh window into how ProPetro’s completion and power services are tracking against evolving North American oil and gas activity. With a positive industry view on U.S. land completions emerging from recent analyst commentary, we’ll explore how this news...

Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor for MASH, reinforcing its focus on next-generation liver disease therapies. This deal adds a complementary clinical-stage asset alongside Rezdiffra’s early commercial traction, potentially broadening Madrigal’s role in MASH treatment combinations and care pathways. We’ll now explore how the Pfizer ervogastat license could reshape Madrigal’s investment...